Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scans reveal why some smokers struggle to quit

NCT ID NCT03442413

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how quickly the body breaks down nicotine and how that affects brain receptors in smokers. Thirteen adult smokers will have PET brain scans after different periods of not smoking, and will receive a tiny amount of nicotine during the scan. The goal is to understand why some people have a harder time quitting, which could lead to better ways to help them stop smoking.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
2-[18F]-FA (a radioactive tracer) and intravenous nicotine
What this could lead to
If successful, this could help explain why some smokers find it harder to quit, potentially guiding personalized smoking cessation treatments.
What could go wrong
This is a very small, early-phase study with only 13 participants, so results may not apply to all smokers. It is designed to gather knowledge, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

13 people

The number who actually took part.

Started

Jun 2018

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants will be 18-65 years of age 2. Self-reported cigarette smoking history of at least 10 cigarettes/day for at least 6 months prior to enrollment 3. Carbon monoxide reading \> 10 ppm at the initial screening session 4. Participants agree to be compliant with all study procedures including smoking abstinence and willingness to complete over-night stays at the Hospital of the University of Pennsylvania 5. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: 1. Women who are pregnant at the time of screening will not be eligible for this study. A urine pregnancy test will be performed in women of childbearing potential at screening. 2. Self-reported regular (daily) use of chewing tobacco, snuff or snus 3. Current enrollment in a smoking cessation or research program involving the use of nicotine substitutes 4. History within one year or currently receiving treatment for substance abuse other than nicotine (e,g,, alcohol, opioids, cocaine, marijuana, or stimulants) 5. Current use of cocaine, methamphetamines or other psychoactive substances per self-report and/or positive urine drug screen at the initial screening session 6. Self-reported current alcohol consumption that exceeds greater than 25 drinks per week in men and 18 drinks per week in women 7. BrAC reading greater than or equal to 0.01% at the initial screening session 8. History of kidney and/or liver disease per medical record review or self-reported 9. Uncontrolled hypertension (defined as Systolic BP \> 160 and/or Diastolic BP \> 100 at the screening intake session) 10. History of Posttraumatic Stress Disorder (PTSD), bipolar disorder, schizophrenia or other psychotic disorder or Attention-Deficit/Hyperactivity Disorder (ADHD) as assessed by medical record review and/or self-report. History of unipolar depression or anxiety disorder may be accepted; current depression or anxiety may be accepted if the severity does not require psychoactive medication as assessed by medical record review and/or self-report. 11. History of head trauma, that in the opinion of an investigator may interfere with the uptake of \[18F\]2-FA, as assessed by medical record review and/or self-report 12. Current use or recent discontinuation (within the last 14 days) of any of the following: 1. Smoking cessation medication (e.g. Zyban, Wellbutrin, Wellbutrin SR, Chantix). 2. Anti-psychotic medications. 3. Certain medications used to treat depression, including SSRIs, Wellbutrin, MAOIs, and tricyclic antidepressants. 4. Prescription stimulants (e.g. Provigil, Ritalin, Adderall). 13. Current use of any of the following: 1. Nicotine replacement therapy (NRT). 2. Tagamet (cimetidine). 3. Heart medications such as digoxin, quinidine, nitroglycerin. Use of these medications may result in ineligibility and will therefore be evaluated on a case-by-case basis by the Study Physician. 4. Anti-coagulants (e.g. Coumadin, Warfarin). 5. Any drug the investigator determines could interfere with scan results. 14. Daily use of any of the following: 1. Opiate-containing medications for chronic pain; If a participant reports taking an opiate-containing medication every day for the 14 days prior to the telephone screen and/or the Intake Session, the participant will be ineligible. 2. Rescue Inhalers (e.g. Albuterol, Proventil, Ventolin, or Maxair). 15. Any contraindication to brain MRI 16. Any current medical condition, psychiatric disorder, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Smoking, tobacco are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Tobacco Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.